Disclosed is a compound for treatment of
Myotonic Dystrophy type 1 having the formula:Wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selected from the group consisting of N, O, S, and C, Z is an optionally substituted
aryl group or optionally substituted heteroaryl, including but not limited to halogenated benzenes, pyridines, substituted
benzene, substituted
pyridine, R2=hydroxy, acyl, alkoxyl, esters, ethers, cyclic ethers, and lactones, R3=H,
alkyl, an optionally substituted
alkyl, aliphatic
ether, ester, cyclic unsaturated and aromatic ring groups, and R1, R4 and R5 are independently selected from the group consisting of
hydrogen,
halogen,
alkyl, and alkoxyl or a pharmaceutically or cosmetically acceptable salt, solvate, or
hydrate thereof.